Transforming growth factor-beta signaling is differentially inhibited by Smad2D450E and Smad3D407E

Miki Kondo1, Hiroyuki Suzuki, Kazuhiko Takehara

  • 1Department of Biochemistry, The Cancer Institute of the Japanese Foundation for Cancer Research (JFCR), Toshima-ku, Tokyo 170-8455, Japan. mit-kato@md.tsukuba.ac.jp

Cancer Science
|January 15, 2004
PubMed

Insights

A novel Smad2 mutant (Smad2D450E) identified in colorectal cancer inhibits transforming growth factor beta (TGF-beta) signaling differently than a previously studied Smad3 mutant. Smad2D450E uniquely impacts Smad3-mediated signaling downstream of phosphorylation and hetero-oligomerization.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Cancer Research

Background:

  • Transforming growth factor beta (TGF-beta) signaling is crucial in cellular processes and often dysregulated in cancer.
  • Smad proteins are key mediators of TGF-beta signaling.
  • A missense mutant of Smad2 (Smad2D450E), identified in colorectal cancer, lacks phosphorylation by TGF-beta signaling.

Purpose of the Study:

  • To investigate the inhibitory effects of the Smad2D450E mutant on TGF-beta signaling.
  • To compare the inhibitory mechanisms of Smad2D450E with a previously characterized Smad3 mutant (Smad3D407E).

Main Methods:

  • Expression of Smad2D450E and Smad3D407E mutants.
  • Assessment of Smad2 and Smad3 phosphorylation.
  • Analysis of Smad protein hetero-oligomerization with Smad4.
  • Evaluation of Smad protein binding to DNA elements.
  • Measurement of transcriptional activity of TGF-beta target genes.

Main Results:

  • Smad2D450E suppressed Smad2 phosphorylation but not Smad3 phosphorylation, unlike Smad3D407E which inhibited both.
  • Smad2D450E reduced Smad2-Smad4 hetero-oligomerization, but not Smad3-Smad4, whereas Smad3D407E affected both.
  • Smad2D450E inhibited Smad3 binding to DNA and transcriptional activity, suggesting a post-hetero-oligomerization inhibitory mechanism.

Conclusions:

  • Smad2D450E and Smad3D407E exhibit distinct inhibitory mechanisms on TGF-beta signaling.
  • Smad2D450E may inhibit Smad3-mediated TGF-beta signaling through a novel pathway affecting nuclear translocation or transcriptional regulation.
  • These findings provide new insights into the complex regulation of TGF-beta signaling in colorectal cancer.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...